|Units||Retail||Members (Not a Member?)|
Cancer antigen 27.29 is used to monitor metastatic carcinoma of the breast. It is a useful measurement when monitoring both the course of disease and response to therapy since there is a direct correlation between the changing levels of CA 27.29 and clinical status.
In a woman with known metastases, a reduction in levels of this marker indicates a good response to treatment while increasing levels indicate resistance to therapy and progressive disease. It has also recently been shown that an elevation of CA 27.29 levels above the upper limit of normal in a woman with no clinical evidence of disease is an early indicator of reoccurrence.
Elevated serum CA 27.29 levels found in women in remission for breast cancer indicated a significant possibility for cancer reoccurrence. However, this test is not a diagnostic screening test.
Fasting is not required for this test. Take all medications as prescribed.
The laboratory services are for informational purposes only. It is not the intention of National Diagnostics, Inc and Life Extension to provide specific medical advice but rather to provide users with information to better understand their health. Specific medical advice including diagnosis and treatment will not be provided. Always seek the advice of a trained health professional for medical advice, diagnosis or treatment.
Both the physician and the testing laboratory are independent contractors with whom National Diagnostics, Inc makes arrangements for your blood tests. Neither National Diagnostics, Inc or Life Extension will be liable for any acts or omissions of the physician, the testing laboratory, or their agents or employees.